What are the comparative rates of sexual dysfunction between individual SSRIs, SNRIs, bupropion and mirtazapine in randomized trials?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Randomized trials and pooled analyses consistently show that serotonergic antidepressants — SSRIs and SNRIs — carry substantially higher rates of treatment-emergent sexual dysfunction than non‑serotonergic agents such as bupropion and, frequently, mirtazapine, with reported prevalence ranges roughly 30–60% for many SSRIs and substantially lower single‑digit to mid‑20% rates for bupropion and some non‑serotonergic agents [1] [2] [3]. Direct randomized comparisons and meta-analyses confirm bupropion and nefazodone as having the lowest rates, while venlafaxine XR and several SSRIs often sit at the high end of risk estimates [4] [2] [5].
1. What the randomized-trial literature actually measures
Randomized trials vary: a small number were designed primarily to measure sexual adverse effects, others included structured sexual-function assessments inside efficacy trials, and systematic reviews draw from these heterogeneous RCTs plus open-label data and pharmacovigilance reports — a mix that shapes reported rates and confidence in comparisons [1] [6] [5].
2. SSRIs and SNRIs: consistently higher rates
Multiple large outpatient samples and systematic reviews report that SSRIs and the SNRI venlafaxine XR are associated with the highest rates of sexual dysfunction — figures cited commonly in the literature put SSRI/SNRI-associated sexual adverse events in the range of about 30%–60% for various sexual domains, and one multicenter sample estimated venlafaxine XR and several SSRIs at ~36%–43% [1] [2] [4].
3. Bupropion and mirtazapine: lower-risk alternatives
Bupropion (both IR and SR) and mirtazapine repeatedly appear as lower‑risk options: prospective multicenter data shows bupropion IR ≈22% and SR ≈25% while mirtazapine estimates vary but are commonly reported substantially lower than many SSRIs (some studies report mirtazapine ~24% and others higher around 36% depending on sample and method) and reviews characterize bupropion and mirtazapine as having little to no effect compared with placebo in monotherapy settings [2] [7] [8] [3]. Pharmacovigilance and network analyses also flag bupropion and mirtazapine among agents with lower reporting rates [5].
4. Head‑to‑head randomized comparisons — what they show and where they conflict
Randomized double‑blind trials that directly compared bupropion to SSRIs found markedly lower rates of orgasmic and overall sexual dysfunction with bupropion versus sertraline or paroxetine in several trials (for example, one trial showed orgasmic dysfunction in 61% of men and 41% of women on sertraline vs 10% and 7% respectively on bupropion) and meta-analyses of RCTs for SSRI-induced dysfunction show bupropion augmentation improved sexual domains in women [4] [6] [9]. Yet some smaller RCTs reported no statistically significant difference between bupropion SR and an SSRI in women, highlighting inconsistency when sample sizes are limited [9].
5. Why exact comparative percentages vary — methodological caveats
Reported rates depend heavily on study design, measurement tool (physician report vs validated patient questionnaires), baseline risk (depression itself causes sexual dysfunction), duration of follow-up, and whether trials were powered to detect sexual adverse effects; pooled estimates therefore differ across reviews (for example, one study reported SSRIs/venlafaxine XR 4–6 times the odds of sexual dysfunction vs bupropion SR in a subpopulation) and pharmacovigilance adds signal‑detection but not incidence per se [2] [5] [1].
6. Clinical takeaways and balanced interpretation
For clinicians and guideline‑minded decision makers, the randomized evidence supports a hierarchy: SSRIs and many SNRIs pose the greatest risk of sexual dysfunction; bupropion and nefazodone consistently show lower rates; mirtazapine is generally lower risk but estimates vary by study; and augmentation with bupropion or switching to a non‑serotonergic agent are evidence‑supported strategies when sexual side effects arise, while acknowledging gaps in high‑quality, large RCTs focused solely on sexual outcomes [1] [6] [8]. The literature is robust enough to inform prescribing choices when sexual function is a priority, but heterogeneity and some conflicting small trials counsel caution in stating precise point estimates for every individual drug [2] [9].